Bal Pharma

Bal Pharma Acquisitions (Net)

The Acquisitions (Net) of Bal Pharma (BALPHARMA.NS) as of Nov 3, 2026 is 38.70 M INR. In the previous year, Acquisitions (Net) was -79.11 M INR — a change of -148.92% (higher).

Acquisitions (Net)

38.70 MINR

YoY

-148.92%

Last updated:

Acquisitions (Net) of Bal Pharma is 2025 38.70 M INR. Acquisitions (Net) of Bal Pharma was 2024 -79.11 M INR. It decreases by -148.92% higher compared to the previous year.

The Bal Pharma Acquisitions (Net) history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Acquisitions (Net)
Date
Acquisitions (Net)
Jan 1, 2018
2.20 M INR
Jan 1, 2019
5.50 M INR
Jan 1, 2020
3.60 M INR
Jan 1, 2021
-15.70 M INR
Jan 1, 2022
-10.20 M INR
Jan 1, 2023
-75.37 M INR
Jan 1, 2024
-79.11 M INR
Jan 1, 2025
38.70 M INR
The Bal Pharma Acquisitions (Net) history
YEARAcquisitions (Net)YoY
38.70 MINR-148.92%
-79.11 MINR+4.96%
-75.37 MINR+638.92%
-10.20 MINR-35.03%
-15.70 MINR-536.11%
3.60 MINR-34.55%
5.50 MINR+150.00%
2.20 MINR+10.00%
2.00 MINR-37.50%
3.20 MINR0.00%
3.20 MINR+100.00%
1.60 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bal Pharma Stock analysis

What does Bal Pharma do? Bal Pharma Ltd. generates revenue through the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company specializes in bulk actives, prescription drugs, generics, and pharma intermediates, targeting therapeutic areas such as anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. Its product portfolio includes APIs like antihistamine, platelet inhibitor, anti-diabetic, and anti-inflammatory agents, alongside finished formulations in tablets, capsules, syrups, and ointments. Key brands such as ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP are marketed to healthcare providers and consumers in these therapeutic segments. The company sells its APIs to other pharmaceutical manufacturers for further processing into finished products, while its finished formulations are distributed to hospitals, pharmacies, and clinics. Brands like AYURFINE and MENOLEAP CAPSULES target specific patient groups, such as those requiring anti-inflammatory or menopause treatment, respectively. The natural medicine line, including AYURSULIN and PROLIFE, caters to consumers seeking alternative treatments in diabetes and reproductive health. Revenue is derived from both B2B sales of APIs and direct B2C or B2B2C sales of branded formulations across multiple therapeutic categories. Bal Pharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bal Pharma stock

Acquisitions (Net) of Bal Pharma is 38.70 M INR in 2025.

Acquisitions (Net) of Bal Pharma changed from -79.11 M INR to 38.70 M INR, representing a -148.92% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Acquisitions (Net) Bal Pharma since 2006 – with annual values, charts, and detailed analysis.

Net acquisitions represent the cash spent on acquiring other businesses, net of divestitures. Large acquisitions can transform a company's growth trajectory.

Acquisitions (Net)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Acquisitions (Net)'s Bal Pharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Bal Pharma

All Key Metrics — Bal Pharma